GSK has announced its acquisition of the privately held company 35Pharma for $950 million in cash, as part of a strategic move to enhance its portfolio of treatments for lung diseases. The acquisition was confirmed on Wednesday, marking a significant investment in the development of new therapies for pulmonary conditions.
At the heart of this deal is an experimental drug known as HS235, which is poised to enter clinical trials for treating pulmonary arterial hypertension (PAH). This condition, characterized by high blood pressure in the lungs, has garnered increasing attention from pharmaceutical companies in recent years. Notably, Merck’s Winrevair received approval for its PAH treatment in 2024 and achieved sales of $1.4 billion the previous year, highlighting the market potential for effective therapies in this area.
The acquisition of 35Pharma aligns with GSK’s broader strategy to strengthen its respiratory portfolio, which has been a key focus for the company. As the demand for innovative treatments in pulmonary health continues to rise, GSK aims to position itself as a leader in this therapeutic space.
GSK’s Chief Executive Officer, Emma Walmsley, emphasized the importance of this acquisition during a press briefing, stating that “the addition of HS235 will enhance our ability to address unmet medical needs in patients suffering from pulmonary arterial hypertension.” The company is optimistic that the drug will provide new options for patients and contribute to the ongoing efforts to combat this serious condition.
The deal is expected to close in the coming months, subject to customary closing conditions. GSK anticipates that the integration of 35Pharma will proceed smoothly, given the alignment of their strategic objectives and commitment to advancing innovative treatments.
With the growing prevalence of PAH, GSK’s investment reflects a broader trend in the pharmaceutical industry, where companies are increasingly focusing on developing specialized therapies that target specific diseases. As competition in the lung health sector intensifies, GSK’s acquisition positions it to leverage its existing expertise and resources to bring HS235 to market.
In conclusion, GSK’s acquisition of 35Pharma for $950 million not only strengthens its pipeline but also underscores its commitment to addressing critical health challenges faced by patients with pulmonary diseases. As the clinical trials for HS235 commence, the pharmaceutical community will be watching closely to see how this new therapy develops and what impact it may have on the treatment landscape for pulmonary arterial hypertension.
